Biotech Values

[drbio45]

It appears that the 25 mg dose is more than enough, so a dosing regimen would probably not be needed for the study.

In the upcomming phase 2 it seems that they should try a maintenance dose of one month for some patients, and 2 months for another group, of course the people getting the maintenance every 2 months would get a placebo, at the in -between months.

I have the feeling that as you say, they could probably get by, with the every 2 month dosing and still beat the competition, but WHAT IF the monthly maintenance improves vision TREMENDOUSLY. Wouldn't it then be worth doing.

They won't know until they try. The phase 2 is not a place to skimp on costs.

They had no choice but to skimp before, because the cash situation and the access to funds, made it neccessary to do the trial the way they did, in order to avoid the black hole of being a biotech without cash. A lot has changed in the past year.

The company's technology would have either been bought out of bankcrupcy or some vc. would have forced a dilutive event that would have caused all the shareholders to get pennies on the dollar. Thank goodness Roy thought of doing the trials in Mexico.